Interleukin-12 Therapy of Cutaneous T-Cell Lymphoma Induces Lesion Regression and Cytotoxic T-Cell Responses
Alain H. Rook(University of Pennsylvania), Eric C. Vonderheid(Ashford and St Peter's Hospitals NHS Foundation Trust), Stuart R. Lessin(Fox Chase Cancer Center), Ryan Shane(Allegheny College), Gary S. Wood(University of Wisconsin–Madison), David M.F. Kao(Allegheny College), Matthew L. Sherman, Elisa K. Yoo(Allegheny College), Rosalie Elenitsas(California University of Pennsylvania), Kenneth Rockwell(Allegheny College), William K. Witmer(Allegheny College)
Cited by 276
Related Papers
Treatment of Cutaneous T-Cell Lymphoma by Extracorporeal Photochemotherapy
|New England Journal of Medicine|1987|1.2k
Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production.
|PubMed|1997|814
Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer
|Journal of Clinical Oncology|2011|657
Pivotal Phase III Trial of Two Dose Levels of Denileukin Diftitox for the Treatment of Cutaneous T-Cell Lymphoma
|Journal of Clinical Oncology|2001|610